Alexion, AstraZeneca Rare Disease

Alexion, AstraZeneca Rare Disease

Alexion, AstraZeneca Rare Disease

Alexion, AstraZeneca Rare Disease
Company Profile

Alexion, AstraZeneca Rare Disease

Boston, United States of America

About Us Leadership Alexion Charitable Foundation Sustainability Our R&D Approach Rare Disease R&D Leadership in Complement Our Pipeline
0Products
0People
0Events
0Locations

Overview

Company details and contact information.

About

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion, AstraZeneca’s Rare Disease group, was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, supportive technologies and healthcare services. Dedicated to continuing its mission as part of AstraZeneca, Alexion recognizes that patients and caregivers are people first, and by understanding their experiences, Alexion is better able to serve their unique needs. Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally. For more information, please visit www.alexion.com. About Alexion, AstraZeneca Rare Disease Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. For more information, please visit www.alexion.com.

Address
121 Seaport Blvd, Boston MA 02186 | 121 Seaport Boulevard, Boston MA 02210, United States of America